#129: ACCP thrombosis guidelines on aspirin in primary prevention; EMA on aliskiren, aprotinin, and orlistat; homocysteine saga: is gene analysis the final chapter?; FDA advisors recommend approval of obesity drug Qnexa; guideline-recommended HF therapies
ACCP thrombosis guidelines on aspirin in primary prevention; EMA on aliskiren, aprotinin, and orlistat; homocysteine saga: is gene analysis the final chapter?; FDA advisors recommend approval of obesity drug Qnexa; guideline-recommended HF therapies (Source: Radio TheHeart.org)
Source: Radio TheHeart.org - February 24, 2012 Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: podcasts
#127: Wine and chocolate: Flavonoid and polyphenol research; clopidogrel plus aspirin: No benefit for stroke prevention; wireless power delivery for LVADs; TRA 2°P: Vorapaxar meets end point but ups bleeding
Wine and chocolate: Flavonoid and polyphenol research; clopidogrel plus aspirin: No benefit for stroke prevention; wireless power delivery for LVADs; TRA 2°P: Vorapaxar meets end point but ups bleeding (Source: Radio TheHeart.org)
Source: Radio TheHeart.org - February 10, 2012 Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: podcasts
ASFH Aspirin and AMD
Guest: P.T.V.M. de Jong, MD, PhD.Department of Ophthalmogenetics, Netherlands Ophthalmic Research InstituteRoyal Netherlands Academy of Arts and SciencesAmsterdam, the Netherlands (Source: As Seen From Here)
Source: As Seen From Here - January 19, 2012 Category: Opthalmology Authors: JYoungMD at gmail.com Source Type: podcasts
ASFH Aspirin and AMD
Guest: P.T.V.M. de Jong, MD, PhD.Department of Ophthalmogenetics, Netherlands Ophthalmic Research InstituteRoyal Netherlands Academy of Arts and SciencesAmsterdam, the Netherlands (Source: As Seen From Here)
Source: As Seen From Here - January 19, 2012 Category: Opthalmology Authors: JYoungMD at gmail.com Source Type: podcasts
The Lancet: October 28, 2011
Discussion of the CAPP2 study, a randomised trial investigating whether aspirin can reduce the risk of familial colorectal cancer. (Source: Listen to The Lancet)
Source: Listen to The Lancet - October 28, 2011 Category: Journals (General) Authors: The Lancet Source Type: podcasts
Proton Pump Inhibitors for Gastroduodenal Damage Related to NSAIDs or Aspirin
Dr. George Triadafilopoulos discusses his special report in the July issue of CGH on use of proton pump inhibitors for clinical management of gastroduodenal damage related to NSAIDs or aspirin. (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - July 2, 2009 Category: Gastroenterology Authors: AGA Source Type: podcasts
The Lancet: May 29, 2009
Colin Baigent discusses the use of aspirin for primary prevention of vascular disease. (Source: Listen to The Lancet)
Source: Listen to The Lancet - May 29, 2009 Category: Journals (General) Authors: The Lancet Source Type: podcasts
JAMA: 2007-05-09, Vol. 297, No. 18, Author in the Room Audio Interview
Interview with Steven R. Steinhubl, MD, author of Aspirin Dose for the Prevention of Cardiovascular Disease. Summary Points: 1. While aspirin is generally a safe drug and extremely effective, with more than 50 million US adults taking it every day for cardiovascular disease prevention, even a very small incidence of adverse effects can have major implications. Consistent with this, one study found that the most common medication leading to an adverse event requiring hospitalization was aspirin for cardiovascular disease prevention. 2. In terms of preventing heart attacks, strokes, or cardiovascular deaths, no clinical tria...
Source: JAMA Author in the Room - July 13, 2007 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts
Aspirin: Initial Heart Attack and Stroke
(Source: MedlinePlus: NLM Director's Comments)
Source: MedlinePlus: NLM Director's Comments - May 15, 2006 Category: Databases & Libraries Authors: National Library of Medicine Source Type: podcasts
